Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir

World Journal of Gastroenterology

Volumn 19, Issue 43, 2013, Pages 7671-7679

  Park, Hana ^a,b   Park, Jun Yong ^a,b   Kim, Seung Up ^a,b   Kim, Do Young ^a,b   Han, Kwang Hyub ^a,b,c,d   Chon, Chae Yoon ^a,b   Ahn, Sang Hoon ^a,b,c,d  

^a CHA University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Liver Cirrhosis Clinical Research Center   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

Antiviral resistance; Chronic hepatitis B; Lamivudine; Suboptimal response; Telbivudine

Indexed keywords

ADEFOVIR; HEPATITIS B (E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENE MUTATION; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARALLEL DESIGN; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS B; LAMIVUDINE; SUBOPTIMAL RESPONSE; TELBIVUDINE;

ADENINE; ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PATIENT SELECTION; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; THYMIDINE; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 84888086554     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i43.7671     Document Type: Article

References (48)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343]
2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/ jama.295.1.65]
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686 [PMID: 16530509 DOI: 10.1053/j.gastro.2005.11.016]
4. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001]
5. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3]
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/ hep.23190]
7. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M, Lai CL. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88 [PMID: 18977053 DOI: 10.1016/ j.jhep.2008.07.023]
8. Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep 2007; 9: 14-22 [PMID: 17335673]
9. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696 [PMID: 12627352 DOI: 10.1086/368083]
10. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-1451 [PMID: 17983801 DOI: 10.1053/j.gastro.2007.08.079]
11. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313 [PMID: 17256746 DOI: 10.1002/hep.21534]
12. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449-454 [PMID: 20646776 DOI: 10.1016/ j.jhep.2010.03.020]
13. Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol 2009; 50: 644-647 [PMID: 19231017 DOI: 10.1016/j.jhep.2009.01.007]
14. Santantonio T, Fasano M, Durantel S, Barraud L, Heichen M, Guastadisegni A, Pastore G, Zoulim F. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther 2009; 14: 557-565 [PMID: 19578241]
15. Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008; 15: 392-398 [PMID: 18221300 DOI: 10.1111/j.1365-2893.2007.00966.x]
16. Xing J, Han T, Liu L, Li Y, Li J, Li Y, Xiao SX. Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil. Zhonghua Ganzangbing Zazhi 2011; 19: 828-832 [PMID: 22433304]
17. Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother 2012; 56: 2941-2947 [PMID: 22430972 DOI: 10.1128/aac.00338-12]
18. Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A, Tennant B, Korba B, Cote P, Marion P, Cretton-Scott E, Schinazi RF, Sommadossi JP. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45: 229-235 [PMID: 11120971 DOI: 10.1128/ aac.45.1.229-235.2001]
19. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588 [PMID: 18094378 DOI: 10.1056/NEJMoa066422]
20. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897 [PMID: 17632041 DOI: 10.1016/j.cgh.2007.05.004]
21. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745-754 [PMID: 17909201]
22. Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, Yuen MF, Chutaputti A, Chao YC, Trylesinski A, Avila C. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int 2011 Oct 12; Epub ahead of print [PMID: 21989925 DOI: 10.1007/s12072-011-9314-7]
23. Han KH, Hong SP, Choi SH, Shin SK, Cho SW, Ahn SH, Hahn JS, Kim SO. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther 2011; 16: 77-87 [PMID: 21311111 DOI: 10.3851/imp1702]
24. Bae SH, Yoon SK, Jang JW, Kim CW, Nam SW, Choi JY, Kim BS, Park YM, Suzuki S, Sugauchi F, Mizokami M. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005; 20: 816-820 [PMID: 16224156]
25. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011; 16: 1169-1186 [PMID: 22155900 DOI: 10.3851/imp1982]
26. Chon YE, Kim SU, Lee CK, Heo J, Kim JK, Yoon KT, Cho M, Lee KS, Kim DH, Choi EH, Park JY, Kim do Y, Chon CY, Han KH, Ahn SH. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antivir Ther 2011; 16: 469-477 [PMID: 21685534 DOI: 10.3851/imp1772]
27. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, Hwang SG, Rim KS, Chon CY, Han KH, Park JY. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53: 1486-1493 [PMID: 21520167 DOI: 10.1002/ hep.24221]
28. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455 [PMID: 19052126 DOI: 10.1056/NEJMoa0802878]
29. Lee JM, Park JY, Kim do Y, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010; 15: 235-241 [PMID: 20386079 DOI: 10.3851/imp1510]
30. Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010; 82: 1835-1842 [PMID: 20872709 DOI: 10.1002/ jmv.21898]
31. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174-S184 [PMID: 19399794 DOI: 10.1002/hep.22900]
32. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25 Suppl 1: 9-19 [PMID: 16103977 DOI: 10.1055/ s-2005-915645]
33. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50: 674-683 [PMID: 19231002 DOI: 10.1016/j.jhep.2008.10.033]
34. Brunetto MR, Lok AS. New approaches to optimize treatment responses in chronic hepatitis B. Antivir Ther 2010; 15 Suppl 3: 61-68 [PMID: 21041905 DOI: 10.3851/imp1625]
35. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495 [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026]
36. Safadi R, Xie Q, Chen Y, Yin YK, Wei L, Hwang SG, Zuckerman E, Jia JD, Lopez P. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. Liver Int 2011; 31: 667-675 [PMID: 21040410 DOI: 10.1111/j.1478-3231.2010.02360.x]
37. Wang LC, Chen EQ, Cao J, Liu L, Wang JR, Lei BJ, Tang H. Combination of Lamivudine and adefovir therapy in HBeAgpositive chronic hepatitis B patients with poor response to adefovir monotherapy. J Viral Hepat 2010; 17: 178-184 [PMID: 19656287 DOI: 10.1111/j.1365-2893.2009.01164.x]
38. Chen EQ ZT, Tang H. Combination of telbivudine and adefovir dipivoxil therapy in chronic hepatitis B patients with poor response to adefovir dipivoxil monotherapy. INT J INFECT DIS 2010; 14 Suppl 2: S18 [DOI: 10.1016/S1201-9712(10)60001-X]
39. McKeage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs 2010; 70: 1857-1883 [PMID: 20836578 DOI: 10.2165/11204330-000000000-00000]
40. Hartwell D, Jones J, Harris P, Cooper K. Telbivudine for the treatment of chronic hepatitis B infection. Health Technol Assess 2009; 13 Suppl 3: 23-30 [PMID: 19846025 DOI: 10.3310/ hta13suppl3/04]
41. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG. A doseranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-1209 [PMID: 16230074 DOI: 10.1053/ j.gastro.2005.06.055]
42. Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101 [PMID: 14699491]
43. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049 [PMID: 16762627 DOI: 10.1053/j.gastro.2006.04.007]
44. Chen EQ, Zhou TY, Bai L, Wang JR, Yan LB, Liang LB, Tang H. Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. Antivir Ther 2012; 17: 973-979 [PMID: 22728692 DOI: 10.3851/imp2190]
45. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; 3: 425-433 [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3]
46. Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4: 386-395 [PMID: 20305758 DOI: 10.1007/s12072-010-9163-9]
47. Li X, Zhong C, Yang S, Fan R, Peng J, Guo Y, Sun J, Hou J. [Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B]. Nanfang Yike Daxue Xuebao 2012; 32: 826-829 [PMID: 22699063]
48. Gane E, Deray G, Piratvisuth T, Chan HLY, Jia J, Ren H, Rasenack J, Manns M, Amarapurkar D, Dong Y, Trylesinski A. Renal function of chronic hepatitis B (CHB) patients improves with telbivudine treatment[R]. Thailand, Bangkok: APASL 2011